Hosted on MSN

MindBio Therapeutics Advances Towards Phase 3 Trials with Software Upgrade

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Mindbio Therapeutics Corp.
Morningstar

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Hosted on MSN

RIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ribomic, Inc. ( (JP:4591)) just unveiled ...
Jane's Information Group

TADTE 2025: Sea acceptance trials of Taiwan's new submarine programme delayed

A model of Taiwanʼs Indigenous Defense Submarine at the Taipei Aerospace & Defense Technology Exhibition 2025. (Janes/Akhil Kadidal) Efforts to conclude sea trials of Taiwan's Indigenous Defense ...
ascopubs.org

Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium

Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized ...
Post and Courier

HopeHealth launches phase 3 clinical trial site to advance lupus research

Florence, S.C. - HopeHealth announced that it is participating in a pivotal phase 3 clinical research study, sponsored by global pharmaceutical company Bristol Myers Squibb (BMS), to evaluate an ...
Nasdaq

Akeso: Gumokimab, Manfidokimab Achieve Primary Endpoints In Phase 3 Trials

(RTTNews) - Akeso Inc. reported positive results from Phase 3 clinical trial of gumokimab or AK111, a fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis.
Morningstar

Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors

DONGGUAN, China, Aug 5, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient ...
Nasdaq

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

MINNEAPOLIS, July 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the ...
The American Journal of Managed Care

Itepekimab Shows Mixed Results in Phase 3 COPD Trials

Itepekimab met the primary endpoint in AERIFY-1, reducing COPD exacerbations, but failed in AERIFY-2 despite initial benefits. Lower-than-expected exacerbation rates, possibly due to the COVID-19 ...
The Hill

FDA should judge drugs on what they do in real life, not just in companies’ clinical trials

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...